Literature DB >> 26025254

Preparing for pre-exposure prophylaxis: perceptions and readiness of Canadian pharmacists for the implementation of HIV pre-exposure prophylaxis.

Deborah Yoong1, Mark Naccarato2, Malika Sharma3, James Wilton4, Heather Senn5, Darrell Hs Tan6.   

Abstract

Pre-exposure prophylaxis (PrEP) has been shown to reduce the risk of HIV transmission but has the potential to cause harm if not used properly. Pharmacists are well-positioned to foster PrEP's efficacy but little is known whether they would endorse it as an HIV prevention tool. The objective of the study was to determine Canadian HIV pharmacists' support for PrEP and to identify current barriers to promoting PrEP. Canadian pharmacists with experience in HIV care were invited to complete an online survey about their experiences, opinions, and learning needs regarding PrEP from December 2012 to January 2013. Among the 59 surveys received, 48 met criteria for final analysis. Overall, 33 (69%) respondents would provide education positively supporting the use of PrEP and 26 (54%) believed Health Canada should approve PrEP for use in Canada. Familiarity with the concept of PrEP and practice characteristics examined did not appear to be significantly associated with support for PrEP in univariable analyses. The principal barriers to promoting PrEP included inadequate drug coverage and insufficient knowledge to educate others. Many Canadian HIV pharmacists would endorse PrEP for high-risk patients; however, wider dissemination of information and lower drug costs may be needed to make PrEP more widely promoted.
© The Author(s) 2015.

Entities:  

Keywords:  AIDS; Canadian; HIV; PrEP; pharmacists; pre-exposure prophylaxis; prevention

Mesh:

Substances:

Year:  2015        PMID: 26025254     DOI: 10.1177/0956462415589896

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  7 in total

1.  Predicting Pharmacist Dispensing Practices and Comfort Related to Pre-exposure Prophylaxis for HIV Prevention (PrEP).

Authors:  B E Meyerson; P C Dinh; J D Agley; B J Hill; D N Motley; G A Carter; W Jayawardene; P T Ryder
Journal:  AIDS Behav       Date:  2019-07

2.  Awareness, knowledge, and attitudes towards human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) among pharmacy students.

Authors:  Sarahmona M Przybyla; Kathleen Parks; Jacob Bleasdale; Joshua Sawyer; Diane Morse
Journal:  Curr Pharm Teach Learn       Date:  2019-02-23

Review 3.  Preexposure Prophylaxis of HIV Infection: the Role of Clinical Practices in Ending the HIV Epidemic.

Authors:  Iryna B Zablotska; Catherine C O'Connor
Journal:  Curr HIV/AIDS Rep       Date:  2017-12       Impact factor: 5.071

4.  Decentralizing the delivery of HIV pre-exposure prophylaxis (PrEP) through family physicians and sexual health clinic nurses: a dissemination and implementation study protocol.

Authors:  Malika Sharma; Allison Chris; Arlene Chan; David C Knox; James Wilton; Owen McEwen; Sharmistha Mishra; Daniel Grace; Tim Rogers; Ahmed M Bayoumi; John Maxwell; Rita Shahin; Isaac Bogoch; Mark Gilbert; Darrell H S Tan
Journal:  BMC Health Serv Res       Date:  2018-07-03       Impact factor: 2.655

5.  Midwest pharmacists' familiarity, experience, and willingness to provide pre-exposure prophylaxis (PrEP) for HIV.

Authors:  Jordan M Broekhuis; Kimberly K Scarsi; Harlan R Sayles; Donald G Klepser; Joshua P Havens; Susan Swindells; Sara H Bares
Journal:  PLoS One       Date:  2018-11-14       Impact factor: 3.240

6.  Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015-2018).

Authors:  Darrell H S Tan; Thomas M Dashwood; James Wilton; Abigail Kroch; Tara Gomes; Diana Martins
Journal:  Can J Public Health       Date:  2020-06-11

7.  Community perspectives on addressing and responding to HIV-testing, pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) among African, Caribbean and Black (ACB) people in Ontario, Canada.

Authors:  Josephine Etowa; Wangari Tharao; Lawrence Mbuagbaw; Shamara Baidoobonso; Ilene Hyman; Suzanne Obiorah; Muna Aden; Egbe B Etowa; Akalewold Gebremeskel; Medys Kihembo; LaRon Nelson; Winston Husbands
Journal:  BMC Public Health       Date:  2022-05-07       Impact factor: 4.135

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.